Key Developments: Targacept Inc (TRGT.O)

TRGT.O on Nasdaq

2.36USD
3:59pm EDT
Change (% chg)

$-0.10 (-4.07%)
Prev Close
$2.46
Open
$2.45
Day's High
$2.45
Day's Low
$2.35
Volume
24,593
Avg. Vol
70,084
52-wk High
$3.23
52-wk Low
$2.15

Search Stocks

Latest Key Developments (Source: Significant Developments)

Targacept and Catalyst Biosciences amend definitive merger agreement
Thursday, 14 May 2015 08:38am EDT 

Targacept Inc and Catalyst Biosciences Inc:Enters into the definitive merger agreement preveiously announced on March 5.On April 6, Targacept disclosed the termination, effective June 1, of the research and license agreement between Catalyst and Wyeth LLC (a wholly owned subsidiary of Pfizer).Amended agreement between Targacept and Catalyst considers the effect on the combined company of the termination of Catalyst's research and license agreement with Wyeth.Boards of directors of both companies have unanimously approved the amendment to the merger agreement.Stifel, Nicolaus & Company, Incorporated is acting as exclusive financial advisor to Targacept and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is serving as its legal counsel.Morrison & Foerster LLP is serving as legal counsel for Catalyst.  Full Article

Targacept announces negative top-line results from Exploratory Study of TC-6499 in Diabetic Gastroparesis
Thursday, 16 Apr 2015 08:30am EDT 

Targacept Inc:Announces top-line results from Phase 1/2 exploratory study of TC-6499 as a treatment for diabetic gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine.In the trial, TC-6499 did not meet the primary endpoint of the study, change in gastric emptying half-time (BT_t1/2), as measured by carbon ((13)C) labeled gastric emptying breath test, relative to placebo.The Phase 1/2 exploratory study was a double-blind, placebo-controlled, randomized, four-way crossover study conducted at seven sites in the United States.  Full Article

Targacept Inc and Catalyst Biosciences Inc enter definitive merger agreement
Thursday, 5 Mar 2015 06:34pm EST 

Targacept Inc and Catalyst Biosciences Inc:Announced that they have entered into definitive agreement to merge two companies.Combined entity, to be named Catalyst Biosciences, Inc., is expected to create financially strong company to harness catalytic power of engineered human proteases to develop biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases.Combined company, anticipates NASDAQ listing with symbol CBIO.As part of proposed transaction, stockholders of Catalyst will initially own about 65 percent of combined company, and operations of both companies will be combined.  Full Article

Targacept Inc appoints interim CFO - Form 8-K
Tuesday, 16 Dec 2014 04:03pm EST 

Targacept Inc:Appoints Mauri K. Hodges to serve on an interim basis as the company‚Äôs vice president, finance and administration, chief financial officer and treasurer, effective immediately.  Full Article

Targacept Inc announces resignation of CFO - Form 8-K
Friday, 14 Nov 2014 08:31am EST 

Targacept Inc:Says on Nov. 10, Alan A. Musso resigned from his position as Senior Vice President, Finance and Administration, Chief Financial Officer and Treasurer of the company.  Full Article

Targacept Inc reaffirms FY 2014 revenue outlook
Wednesday, 6 Aug 2014 07:35am EDT 

Targacept Inc:Says it continues to not expect significant operating revenues for FY 2014.  Full Article

Targacept Inc's phase 2b clinical trial in Alzheimer's disease does not show superiority of TC-1734 over donepezil
Monday, 14 Jul 2014 03:06pm EDT 

Targacept Inc:Announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer's disease.In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer's disease, after 52 weeks of treatment.Trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil.Co-primary endpoints for the study were measures of cognitive function and global function.Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile.  Full Article

Targacept Inc gives FY 2014 revenue outlook
Thursday, 13 Feb 2014 07:30am EST 

Targacept Inc:Says for FY 2014 it does not expect significant operating revenues.FY 2014 revenue of $0.50 mln - Thomson Reuters I/B/E/S.  Full Article

Targacept Inc appoints John P. Richard as Chairman
Wednesday, 8 Jan 2014 08:55am EST 

Targacept Inc:Says John P. Richard has been appointed as the company's Chairman of the Board effective Jan. 1.  Full Article

Targacept Inc announces negative top-line results from Phase 2b clinical trial of TC-5619 in Schizophrenia
Monday, 16 Dec 2013 04:05pm EST 

Targacept Inc:Says top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.Says in the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the Scale for the Assessment of Negative Symptoms (SANS) after 24 weeks versus placebo.Says iIn addition, TC-5619 did not demonstrate improvement on the key secondary measures of cognitive function.Says TC-5619 exhibited a benign safety and tolerability profile in the study.  Full Article

Search Stocks